Published in BMJ on January 06, 2006
Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG (2012) 1.57
Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med (2009) 1.48
Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study. BMJ (2009) 1.20
HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer (2011) 1.10
When to test women for human papillomavirus. BMJ (2006) 0.76
When to test women for human papillomavirus: take this opportunity to screen for anal cancer too. BMJ (2006) 0.75
Cost and logistics of alternative roll-out options for implementing human papillomavirus testing as a triage in cervical screening: results of the sentinel sites study. Br J Cancer (2012) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
The cervical cancer epidemic that screening has prevented in the UK. Lancet (2004) 7.72
2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA (2002) 6.55
Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ (2001) 6.48
Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 5.39
Human papillomavirus testing in primary cervical screening. Lancet (1995) 5.09
Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med (2000) 4.73
Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst (2004) 3.20
Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making (2002) 2.53
Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA (2002) 2.29
Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol (2000) 2.00
Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer (1998) 1.36
An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer (2004) 1.21
Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ (2003) 0.99
Liquid-based cytology in cervical screening: a rapid and systematic review. Health Technol Assess (2000) 0.90
Management of carcinoma of the cervix. Practitioner (1980) 0.82
HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol (2009) 4.99
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet (2005) 4.20
Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol (2013) 3.95
Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J (2006) 3.65
WITHDRAWN: Case management for people with severe mental disorders. Cochrane Database Syst Rev (2011) 3.62
Ultrasonography in the diagnosis and management of developmental hip dysplasia (UK Hip Trial): clinical and economic results of a multicentre randomised controlled trial. Lancet (2002) 3.19
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making (2002) 2.96
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ (2006) 2.67
Could targeted food taxes improve health? J Epidemiol Community Health (2007) 2.66
Missing... presumed at random: cost-analysis of incomplete data. Health Econ (2003) 2.38
Treatment pathways, resource use, and costs of endovascular coiling versus surgical clipping after aSAH. Stroke (2007) 2.34
Patellar resurfacing in total knee replacement: five-year clinical and economic results of a large randomized controlled trial. J Bone Joint Surg Am (2011) 1.84
Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health (2013) 1.77
Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int (2004) 1.68
Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin (2006) 1.65
Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol (2013) 1.64
Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ (2011) 1.59
Ageing and health-care expenditure: the red herring argument revisited. Health Econ (2004) 1.52
Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies. Int J Urol (2014) 1.49
Six year follow-up of a clinical sample of self-harm patients. J Affect Disord (2009) 1.48
Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ (2011) 1.46
The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen (2012) 1.46
Modelling income group differences in the health and economic impacts of targeted food taxes and subsidies. Int J Epidemiol (2009) 1.39
Health care expenditures and ageing: an international comparison. Appl Health Econ Health Policy (2003) 1.39
Placebo use in the United kingdom: results from a national survey of primary care practitioners. PLoS One (2013) 1.37
Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res (2009) 1.35
A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer (2011) 1.34
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart (2006) 1.26
Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected. Int J Cancer (2005) 1.18
Cost-effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia from 33 countries: economic evaluation of the Magpie Trial. BJOG (2006) 1.18
The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales. Cancer Epidemiol Biomarkers Prev (2007) 1.15
Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. BMJ (2006) 1.14
Lead-time in the European Randomised Study of Screening for Prostate Cancer. Eur J Cancer (2010) 1.13
Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set. BMJ Open (2012) 1.12
Standardization of Gleason grading among 337 European pathologists. Histopathology (2013) 1.09
Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen (2012) 1.08
Resource use and costs associated with coeliac disease before and after diagnosis in 3,646 cases: results of a UK primary care database analysis. PLoS One (2012) 1.04
Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making (2009) 1.04
False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer (2011) 1.02
Let's prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation. Cardiovasc Diabetol (2012) 0.98
Reporting the cost-effectiveness of interventions with nonsignificant effect differences: example from a trial of secondary prevention of coronary heart disease. Int J Technol Assess Health Care (2003) 0.98
Healthcare and social services resource use and costs of self-harm patients. Soc Psychiatry Psychiatr Epidemiol (2010) 0.93
Point-of-care testing for the analysis of lipid panels: primary care diagnostic technology update. Br J Gen Pract (2012) 0.92
Automation-assisted versus manual reading of cervical cytology (MAVARIC): a randomised controlled trial. Lancet Oncol (2010) 0.90
The D-Dimer test in combination with a decision rule for ruling out deep vein thrombosis in primary care: diagnostic technology update. Br J Gen Pract (2012) 0.90
Cost-utility analysis of physiotherapy treatment compared with physiotherapy advice in low back pain. Spine (Phila Pa 1976) (2006) 0.90
Time to death and health expenditure: an improved model for the impact of demographic change on health care costs. Age Ageing (2004) 0.90
Responsiveness of objective, disease-specific, and generic outcome measures in patients with chronic low back pain: an assessment for improving, stable, and deteriorating patients. Spine (Phila Pa 1976) (2006) 0.90
Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med (2011) 0.89
Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer. Int J Cancer (2006) 0.89
Systematic review of resource utilization in the hospital management of deliberate self-harm. Psychol Med (2006) 0.89
Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom. Cost Eff Resour Alloc (2010) 0.88
Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands. Cancer Epidemiol Biomarkers Prev (2009) 0.87
Evaluation of the use of digital images for a national prostate core external quality assurance scheme. Histopathology (2011) 0.87
The impact of ageing on expenditures in the National Health Service. Age Ageing (2002) 0.87
The positive experience of screening quality among users of a cervical cancer detection center. Arch Med Res (2002) 0.86
The effect of diabetes complications on health-related quality of life: the importance of longitudinal data to address patient heterogeneity. Health Econ (2013) 0.86
The valuation of prenatal life in economic evaluations of perinatal interventions. Health Econ (2009) 0.85
Coronary artery bypass grafting in high-RISk patients randomised to off- or on-Pump surgery: a randomised controlled trial (the CRISP trial). Health Technol Assess (2014) 0.84
A cost-benefit analysis using contingent valuation techniques: a feasibility study in spinal surgery. Value Health (2007) 0.84
Estimating the costs of surgical innovations: the case for subthalamic nucleus stimulation in the treatment of advanced Parkinson's disease. Mov Disord (2003) 0.84
Point-of-care INR coagulometers for self-management of oral anticoagulation: primary care diagnostic technology update. Br J Gen Pract (2012) 0.83
Improving hand-washing performance - a crossover study of hand-washing in the orthopaedic department. Ann R Coll Surg Engl (2006) 0.82
Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology (2014) 0.81
A systematic review and critical assessment of health state utilities: weight change and type 2 diabetes mellitus. Pharmacoeconomics (2012) 0.81
Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score. Qual Life Res (2012) 0.81
Screening for breast cancer in India--is it an appropriate strategy? J Natl Cancer Inst (2008) 0.81
Point-of-care blood test for ketones in patients with diabetes: primary care diagnostic technology update. Br J Gen Pract (2011) 0.80
The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies. J Clin Virol (2005) 0.80
Dermoscopy for the diagnosis of melanoma: primary care diagnostic technology update. Br J Gen Pract (2011) 0.79
Mobile phone use for contacting emergency services in life-threatening circumstances. J Emerg Med (2011) 0.78
Cost-effectiveness of pre-referral antimalarial, antibacterial, and combined rectal formulations for severe febrile illness. PLoS One (2010) 0.78
Improving clinical reality in chronic obstructive pulmonary disease economic modelling : development and validation of a micro-simulation approach. Pharmacoeconomics (2013) 0.78
Economic evaluations in bipolar disorder: a systematic review and critical appraisal. Bipolar Disord (2014) 0.78
Spirometry in primary care for case finding and management of chronic obstructive pulmonary disease primary care diagnostic technology update. Br J Gen Pract (2011) 0.77
Assessing the amount of unscheduled screening ("contamination") in the control arm of the UK "Age" Trial. Cancer Epidemiol Biomarkers Prev (2010) 0.75
Primary care diagnostic technology update: point-of-care testing for glycosylated haemoglobin. Br J Gen Pract (2011) 0.75
Point-of-care testing for coeliac disease: primary care diagnostic technology update. Br J Gen Pract (2013) 0.75
The Oxford Renal (OxRen) cross-sectional study of chronic kidney disease in the UK. BMJ Open (2013) 0.75
Making amends for negligence. BMJ (2004) 0.75
The multinational nature of cost-effectiveness analyses alongside multinational clinical trials. Value Health (2010) 0.75
Oral corticosteroid use for clinical and cost-effective symptom relief of sore throat: study protocol for a randomized controlled trial. Trials (2014) 0.75
Suspected adverse reactions, 2002. Vet Rec (2003) 0.75
Screening sigmoidoscopy for colorectal cancer. Lancet (2003) 0.75
Liability, insurance and medical practice. J Health Econ (2007) 0.75
Assessing the health benefits of tackling climate change. BMJ (2011) 0.75